Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Horizon Therapeutics
Biotech
Amgen disappears lung disease program after phase 2 fail
Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any primary or secondary endpoints.
Gabrielle Masson
Oct 30, 2024 5:59pm
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
Amgen's lupus bets continue to tumble, even those on the Horizon
Jul 24, 2023 8:59am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm
Selecta, Sobi rout gout in phase 3 trials to take on Horizon
Mar 21, 2023 7:40am
J&J CMO to leave after 20-year executive tenure—Chutes & Ladders
Jan 27, 2023 9:30am
